Biotechnology News

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically...

The supplemental application for Toripalimab plus chemotherapy as perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC has been accepted by the NMPA.

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically...

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has...

Mechelen, België; 21 juli 2026, 22.01 CET; gereglementeerde informatie In het kader van het op 9 juni 2026 aangekondigde inkoopprogramma maakt Lakefront Biotherapeutics NV (Euronext & NASDAQ:...

Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT)...

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks

U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026Gen 2 Monarch device provides an enhanced patient experience while delivering clinically proven therapeutic stimulation of...

SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Revagenix, Inc., a biopharmaceutical company developing targeted, purpose-built medicines for serious chronic diseases, today announced the promotion...

Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA...